There is a chance that, one day, this company will be taken over. It will also pop when J&J gets the OK on the Animus/Dexcom artificial pancreas which is before the FDA. The future will probably bring respectable increases in quarter by quarter sales and their first profitable quarter; they are already cash flow positive. They dominate the CGM market, so I don't think competition is a worry. They have just scratched the surface of foreign sales. These are the positives.
All of the above should increase the price, but from what base? If the market corrects, so will the price of DXCM. Also, insiders have been dumping shares like crazy, check it out.
If you are willing to hold for the long term you should do well. The call is yours, good luck.
I am surprised that no one has commented on a near 6% up move on 7.3 million shares. I don't remember that kind of volume since October of 2013. Maybe this thing can recover some of what it lost in the past few weeks. Take care.
Does anyone know why the stock has dropped, and on volume, in the the past several days? I would love to buy more, but this decline on volume has me wondering what some big player(s) may know. Good luck.
Not all of their posts are fake. I posted a complimentary post a few weeks ago and these jerks have reposted my post under different names several times. The funny thing is, I complained about the huge amount of spam on this board and they used that comment also.
The short interest went from 7.4 million shares on 6-30 to 9.7 million on 7-15, according to the info on NASDAQ.com. There was a brief story on Forbes about it a couple of days ago, but I just saw the article today when I was looking for some reason for the decline. I can't understand why the increase in short interest, but those shares that have been sold short have to be bought back at some time. I just bought some CMLS on Friday and may buy more.
Thanks, this was a great post and article. The spammers have taken over some of these boards, but I keep checking for good stuff like this post.
I don't think so. If they are bought out it would probably be by a company that is involved in the diabetes care field. I think J&J would be a more likely candidate.
Maybe not all of the disappointing news is out. If there is going to be news that will move the stock like it has been moving the past few days why doesn't the company pre-announce?
I nibbled on some at 6.70; the rest of my shares were purchased at higher prices. Wish I new why the shares have dropped the past few days. Hope someone doesn't know something that I don't.
The government does provide the majority of funds for the work that they do, but they have been raising more money in marine fuel taxes than they have been spending and Congress is agitating to loosen the purse strings. It won't be long before the Panama Canal's widening work is done and not all ports are prepared for the larger ships, yet. The biggest positive on the horizon is the billions of dollars that BP is expected to pay the government and Gulf states in settlement for the oil spill with much of that money directed toward beach and wetland reclamation which is the company's most profitable line of work.
I have been in GLDD for a few years, also, and I'm waiting for the BP news before I get out. I have been thinking about getting in and out of the stock to play these forty and fifty cent moves of the past few months.
Yes, Gabelli (GAMCO) filed a 13D on 3-31. It is interesting that they filed a 13D, indicating an activist position, and not the usual 13G, a passive investment, that most mutual funds file.
Where are the comments of support or explanation from management and the analysts that cover this company? One would think that after hefty percentage drops for the past few days someone would step up and keep us, the shareholders, informed. If this company has a future the price right now should be enticing management to buy some shares, but nothing as far as I can see. Is this a bear raid or is the other shoe about to drop? Maybe the indictment is like the old saying about when a one cockroach is found there are probably others. Well, at least no one has resigned "to pursue other interests" --- yet.
Good luck, all.
You are correct. According to a synopsis of the show on The Street, "Grasso said that he was a buyer of E-Trade Financial even after the strong week, where shares gained 10%, citing the upside momentum is not finished." The story was in E*Trade's headlines on Saturday, July 27 under the title, " 'Fast Money' Recap: Housing Stocks".
Down close to over 4% Friday and down over 5% today. This reminds me of last quarter when they kept delaying the earnings release and the stock tanked for a few days before they announced a big earnings miss.
Here is a quote from an August 19, 2011 Bloomberg interview, "If DexCom can double its stock price to $20 or more as a result, Gregg said he’d be open to takeover bids." The result he spoke of, was the introduction of the new/current CGM. He also said the company should be profitable, but he subsequently increased his spending, purchasing a software company and boosting research so the profitability requirement may no longer be on the table.
I am not counting on a buyout, but the story speaks for itself. If you want to read the whole story, look on the internet for the title, Device Maker DexCom May Be for Sale in 2012, CEO Gregg Says. Sorry for not providing a link, but Yahoo has been deleting my posts with links attached, at least that has been my experience.
Good luck, all.
These are some excerpts from a 3-28-13 article from the diaTribe website.
In February, Dexcom submitted an application to expand the label for the G4 Platinum CGM (continuous glucose monitor) to pediatric patients who are as young as two years old. The FDA normally responds to these applications after 180 days, and we expect a decision from the agency during the second half of 2013. Currently, the G4 is only approved for those who are 18 years and older. Though some children are now using the CGM, they are using it “off-label,” and not all healthcare providers (HCPs) are comfortable prescribing therapies in this way.
Dexcom is also working on a new remote monitoring product, Dexcom Share. The product is a cradle that holds the G4 Platinum receiver and plugs into a power outlet at a user’s bedside. Data from the G4 Platinum are then sent via the cradle (using Bluetooth) to a nearby smartphone. That phone then uploads the data to a web-based platform, where it can be monitored by parents or caregivers on their own cellphones. At the ATTD conference, Dexcom showed a picture of a father on a business trip in a taxi, checking his phone with a sigh of relief that his daughter’s CGM reading was 150 mg/dl.